Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 10/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13932708 | 0.91 | KCNH2 (0.63) | KCNH2POLBMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL4475502 | 0.88 | KCNH2 (0.60) | KCNH2POLBMAPK1SMN1; SMN2KMT2A | |
| SCHEMBL4456998 | 0.88 | KCNH2 (0.60) | KCNH2POLBMAPK1SMN1; SMN2KMT2A | |
| SCHEMBL4459637 | 0.88 | KCNH2 (0.60) | KCNH2POLBMAPK1SMN1; SMN2KMT2A | |
| SCHEMBL4472864 | 0.87 | KCNH2 (0.63) | KCNH2 | |
| SCHEMBL4475302 | 0.85 | EPHX2 (0.53) | KCNH2 | |
| SCHEMBL4457002 | 0.85 | SLC6A9 (0.55) | KCNH2POLBMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL5501475 | 0.81 | SLC6A9 (0.52) | KCNH2MEN1KMT2A | |
| SCHEMBL4462507 | 0.81 | SLC6A9 (0.52) | KCNH2 | |
| SCHEMBL4465490 | 0.81 | EPHX2 (0.49) | KCNH2POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511077-B2 | Diamine calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-31 | — | — | US | claimed |
| EP-1846365-A1 | DIAMINE CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2007-10-24 | — | — | EP | claimed |
| US-20060235050-A1 | Diamine calcium channel blockers | NUEROMED TECHNOLOGIES, INC. (CA) | 2006-10-19 | — | — | US | claimed |
| WO-2006084369-A1 | DIAMINE CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2006-08-17 | — | — | WO | claimed |
| US-7511077-B2 | Diamine calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-31 | — | — | US | disclosed |
| US-20060235050-A1 | Diamine calcium channel blockers | NUEROMED TECHNOLOGIES, INC. (CA) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235050-A1 | Diamine calcium channel blockers | CACNA1G, CACNA1H, CACNA1I | KCNH2 44/4885POLB 3273/4885MAPK1 2670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.